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Chitotriosidase is a chitinase that is massively ex-
pressed by lipid-laden tissue macrophages in man. Its
enzymatic activity is markedly elevated in serum of pa-
tients suffering from lysosomal lipid storage disorders,
sarcoidosis, thalassemia, and visceral Leishmaniasis.
Monitoring of serum chitotriosidase activity in Gaucher
disease patients during progression and therapeutic
correction of their disease is useful to obtain insight in
changes in body burden on pathological macrophages.
However, accurate quantification of chitotriosidase lev-
els by enzyme assay is complicated by apparent sub-
strate inhibition, which prohibits the use of saturating
substrate concentrations. We have therefore studied the
catalytic features of chitotriosidase in more detail. It is
demonstrated that the inhibition of enzyme activity at
excess substrate concentration can be fully explained by
transglycosylation of substrate molecules. The potential
physiological consequences of the ability of chitotriosi-
dase to hydrolyze as well as transglycosylate are dis-
cussed. The novel insight in transglycosidase activity of
chitotriosidase has led to the design of a new substrate
molecule, 4-methylumbelliferyl-(4-deoxy)chitobiose.
With this substrate, which is no acceptor for transglyco-
sylation, chitotriosidase shows normal Michaelis-
Menten kinetics, resulting in major improvements in
sensitivity and reproducibility of enzymatic activity
measurements. The novel convenient chitotriosidase en-
zyme assay should facilitate the accurate monitoring of
Gaucher disease patients receiving costly enzyme
replacement therapy.
Chitin, the linear polymer of  1,4-linked N-acetylglu-
cosamine, is a structural component of cell walls and coatings
of many organisms. For a long time it was thought that mam-
mals are unable to produce endoglucosaminidases that frag-
ment chitin. Investigations on Gaucher disease led to the ser-
endipitous discovery of a functional endogenous chitinase in
man (1–3). It was observed that serum samples from Gaucher
patients show a 1000-fold elevated capacity to hydrolyze
4-methylumbelliferyl--D-chitotriose. The responsible enzyme,
named chitotriosidase, was shown to be able to cleave natural
chitin and a variety of artificial chitin-like substrates such as
4-methylumbelliferyl and p-nitrophenyl chitooligosaccharides.
Chitotriosidase belongs to the family 18 of glycosylhydrolases
and is highly homologous to chitinases from lower organisms.
The enzyme consists of a N-terminal TIM-barrel structure con-
taining the catalytic groove and a C-terminal chitin-binding
domain connected by a short hinge region. The crystal struc-
ture of the 39-kDa catalytic domain and its complexes with a
chitooligosaccharide and allosamidin has been described re-
cently (4). The structures reveal an elongated active site cleft,
compatible with binding long chitin polymers. The catalytic
center of chitotriosidase closely resembles that of chitinases
from lower organisms like chitinase A/B from Serratia marc-
escens. The catalytic reaction of family chitinases takes place
through a retaining mechanism, resulting in -anomers by
hydrolysis of  1,4-glycosidic linkages. The reaction is initiated
by distortion of the pyranose ring of the (1) sugar moiety in
the active site and protonation of the glycosidic oxygen by a
protonated acidic residue forming a covalent oxazolinium ion
intermediate. The subsequent nucleophilic attack differs from
classical reaction mechanisms of retaining enzymes such as
lysozyme (5) in that it involves the N-acetyl group of the (1)
sugar, rather than a carboxylate side chain on the protein, a
so-called substrate-assisted mechanism (6, 7).
Chitotriosidase is selectively expressed in chronically acti-
vated tissue macrophages, like the lipid-laden storage cells
that accumulate in large quantities in various tissues of Gau-
cher patients (8). Tissue macrophages largely secrete newly
synthesized 50-kDa chitotriosidase, but about one-third is di-
rectly routed to lysosomes and proteolytically processed to the
39-kDa unit that remains catalytically active (9). Intriguingly,
one in every three individuals from various ethnic groups car-
ries one abnormal chitotriosidase gene with a 24-bp duplication
that prevents production of enzyme (10). About 6% of the pop-
ulation is homozygous for this mutant allele and consequently
completely lacks chitotriosidase activity. In analogy to the
function of homologous chitinases in plants, the physiological
role of chitotriosidase is most likely in innate immunity toward
chitin containing pathogens. An increased risk for nematode
infection has indeed been described for chitotriosidase-deficient
individuals (11).
Pathological tissue macrophages in specific disease condi-
tions massively express chitotriosidase. A shared feature of
such cells is accumulation of lipid material in the lysosomal
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apparatus. The molecular mechanism that underlies the
tightly controlled expression of chitotriosidase is not yet
known. In serum of patients suffering from lysosomal lipid
storage disorders (12), thalassemia (13), sarcoidosis, and vis-
ceral Leishmaniasis (1), as well as in cerebral spine fluid of
patients with multiple sclerosis, significantly elevated chito-
triosidase activities are detectable using artificial chromogenic
and fluorogenic substrates. The abnormality is exploited for
diagnostic and monitoring purposes. For example, the efficacy
of the extremely costly enzyme replacement therapy of Gau-
cher patients is monitored by following corrections in plasma
chitotriosidase activity levels (8, 14). However, accurate quan-
tification of chitotriosidase levels by enzyme assay is prohibited
by apparent substrate inhibition (1). The inevitable use of
subsaturating substrate concentrations reduces the reproduc-
ibility and sensitivity of the assay and has hampered its wide-
scale application outside expert laboratories.
We have studied the molecular basis for the apparent sub-
strate inhibition of chitotriosidase in more detail. The informa-
tion obtained allowed us to design a novel artificial substrate
that can be used for a substantially improved enzyme activity
assay. The results of the study are here reported and discussed.
MATERIALS AND METHODS
Human Recombinant 50-kDa Chitotriosidase—Enzyme was purified
from the medium of stably transfected baby hamster kidneys cells using
the full-length human chitotriosidase cDNA cloned in the pNUT vector
(4). The enzyme was purified by sequential chromatofocussing, isoelectro-
focussing, and gel filtration (2). Chitin oligosaccharides were purchased
from Seikagu Kogyo. All other chemicals, including 4-methylumbellif-
erone, p-nitrophenol, and their conjugates with chitooligosaccharides,
were purchased from Sigma, Aldrich, or Baker.
Enzyme Activity Measurements—The conventional enzyme assays
with commercial artificial fluorogenic or chromogenic substrates were
performed exactly as described before (1). Briefly, enzyme preparations
were incubated at 37 °C with 22 M 4-MU1-chitooligosaccharides or
with 220 M PNP-chitooligosaccharides in McIlvain buffer (100 mM
citric acid, 200 mM sodium phosphate, pH 5.6) containing 1 mg/ml
bovine serum albumin. The enzyme assay was stopped by addition of
excess 0.3 M glycine-NaOH, pH 10.3. Formed 4-methylumbelliferone
was detected fluorometrically (excitation at 445 nm; emission at 366
nm); formed PNP was detected spectrophotometrically at 405 nm.
The optimal assay conditions with the newly synthesized 4-MU-(4-
deoxy)chitobiose were at 114 M in the same buffer. A 35 mM stock
solution of the novel substrate was prepared in Me2SO.
Chitooligosaccharide Analysis—Isocratic HPLC chromatography
with a Prevail carbohydrate ES column (Alltech), and UV detection at
214 nm was used to analyze chitooligosaccharides. The injection volume
was 10 l, the flow rate of the eluent (62:28 (w/w) acetonitrile:H2O) was
1 ml/min.
Synthesis of the Novel Substrate 4-MU-(4-deoxy)chitobiose—Octa-
acetyl chitobioside (1), prepared by acetolysis of chitin (15), was trans-
formed into the partially protected disaccharide (2) according to a
previously reported procedure (16). Hydrolysis of the acetate groups
followed by regioselective introduction of the 4-6-benzylidene group,
acetylation and final acidic removal of the benzylidene moiety, rendered
2 with a yield of 41%. Regioselective benzoylation of the 6-hydroxyl
function in 2 with 1-(benzyloxy)benzotriazole (17) and subsequent es-
terification with 1,1-thiocarbonyldiimidazole rendered key intermedi-
ate 3 with a 53% yield. Barton deoxygenation (18) of 3 was accom-
plished by treatment with tributyltin hydride and a catalytic amount of
azoisobutyronitrile in toluene, yielding 4-deoxyheptaacetyl chitobio-
side (4) with a 72% yield. Subsequent chlorination to 5, followed by
condensation with sodium 4-methylumbelliferonate, and final de-O-
esterification (19) rendered homogeneous 4-MU-(4-deoxy)chitobiose,
compound 6, with a 20% yield.
RESULTS
Transglycosylation—The complex relationship of increasing
concentrations of 4-methylumbelliferyl chitobiose, triose, and
tetraose substrates with the rate of fluorescent (4-MU;
4-methylumbelliferone) product formation is depicted for pure
recombinant chitotriosidase (Fig. 1). It can be seen that at
higher substrate concentrations less product is formed, nearly
independent of the chemical nature of the substrate. Identi-
cally shaped curves were obtained for the corresponding p-
nitrophenyl substrates and the rate of colored p-nitrophenol
formation (not shown). This suggests that the concentration of
N-acetylglucosamine moieties at the non-reducing end of the
substrate molecules is somehow critical. The finding prompted
us to examine the possibility of some transglycosylation event
involving these moieties. For this purpose, pure recombinant
chitotriosidase was incubated with 4-methylumbelliferyl--N-
acetylglucosamine, p-nitrophenyl chitobiose, or a combination
of both compounds. Fig. 2 shows that, as expected, no fluores-
cent 4-MU is formed upon incubation of enzyme with both
compounds separately. In sharp contrast, incubation with the
mixture of both compounds results in formation of fluorescent
4-MU after a lag phase. Transglycosylation offers an attractive
explanation for the outcome of the experiment, as schemati-
cally presented in Fig. 2 (right side). As an initial step, chito-
triosidase removes a chitobiose moiety from the PNP-chitobiose
substrate. Next, the oxazolinium transition state intermediate
may either use H2O or the hydroxyl at the C-4 position in
4-MU-N-acetylglucosamine as acceptor. The latter reaction re-
sults in formation of 4-MU-chitotriose, which after some time is
cleaved by chitotriosidase to yield fluorescent 4-MU.
To investigate the ability of chitotriosidase to transglycosy-
late natural chitooligosaccharides, pure recombinant enzyme
was incubated with 4-methylumbelliferyl--N-acetylglucos-
amine and chitopentaose of p-nitrophenyl chitobiose. 10-fold
larger amounts of fluorescent 4-MU are formed in the presence
of chitopentaose as compared with p-nitrophenyl chitobiose,
indicating that the natural oligosaccharide can act as donor in
the transglycosylation reaction.
Fig. 3 shows that upon incubation of 5 mM chitopentaose
with recombinant chitotriosidase, not only chitobiose and chi-
totriose, but also chitotetraose, and even chitohexaose and
chitoheptaose, are formed. Since chitotriosidase is unable to
remove or add a single N-acetylglucosamine moiety, formation
of chitotetraose demonstrates that chitotriosidase can exert
transglycosidase activity toward chitooligosaccharides. The
formation of small amounts of chitoheptaose points in the same
direction. The total recovery of glucosamine units in the exper-
iment is virtually 100%. It was noticed that meanwhile un-
equal amounts of chitobiose and chitotriose are formed. Appar-
ently, the transglycosidase activity of chitotriosidase is very
considerable, and predominantly chitobiose is donated to ac-
cepting chitooligosaccharides.
1 The abbreviations used are: 4-MU, 4-methylumbelliferyl; PNP, p-
nitrophenyl; HPLC, high performance liquid chromatograpy; AMCase,
acidic mammalian chitinase.
FIG. 1. Comparison of chitotriosidase activity with different
4-MU-(GlcNac) substrates. The hydrolysis of 4-MU-chitobiose (E),
4-MU-(GlcNac)-chitotriose (), and 4-MU-(GlcNac)-tetraose () sub-
strates by 39- and 50-kDa isoforms of recombinant chitotriosidase was
compared at different substrate concentrations. A, absolute values for
enzyme activity; B, relative activities defined as percentage of maximal
activity (closed symbols, 39-kDa chitotriosidase; open symbols, 50-kDa
chitotriosidase).
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The apparent substrate inhibition with 4-MU-chitooligosac-
charide substrates can be fully explained by the transglycosi-
dase capacity of chitotriosidase (see Scheme 1). With increasing
concentration of 4-MU-chitobiose there is increasing formation
of 4-MU-chitotetraose by transglycosidase activity. Chitobiose
units can be subsequently transferred from 4-MU-chitotetraose
to 4-MU-chitobiose molecules, a futile cycle generating no new
products and not releasing fluorescent 4-MU. The experi-
menter observes this process as inhibition of enzyme activity,
since that is monitored by formation of fluorescent 4-MU.
Design and Synthesis of Novel Substrate—The realization
that ongoing transglycosylation is the cause of the problems
encountered with the measurement of enzymatic activity of
chitotriosidase using artificial chitooligosaccharide substrates
stimulated us to design a novel substrate molecule that is
lacking a hydroxyl at the C-4 position of the non-reducing
FIG. 2. Demonstration of transglycosylation with artificial chitooligosaccharides. Left-hand side, recombinant 50-kDa chitotriosidase
was incubated for different time periods with 2.7 mM PNP-chitobiose (A), with 1.6 mM 4-MU-N-acetylglucosamine (B), or with the mixture of both
substrates (C). Released 4-MU (f) and PNP (Œ) were detected as described under “Materials and Methods.” arbs, arbitrary units. Right-hand side,
explanation of result.
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N-acetylglucosamine. A novel compound, 4-methylumbel-
liferyl-N-acetylglucosamine-4,1-(4-deoxy)-N-acetylglucosamine
(4-MU-(4-deoxy)chitobiose) was synthesized, exactly as de-
scribed under “Materials and Methods” (see Fig. 4 for its chem-
ical structure and route of synthesis). We envisioned that this
compound should only be able to act as substrate for hydrolysis
but not as acceptor for transglycosylation. Fig. 5 shows for pure
recombinant chitotriosidase the relationship between the rate
of fluorescent 4-MU formation and the concentration of 4-MU-
chitobiose and 4-MU-(4-deoxy)chitobiose, respectively. Normal
Michaelis-Menten kinetics occurs with 4-MU-deoxychitobiose
as substrate, sharply contrasting to the marked substrate in-
hibition with 4-MU-chitobiose. This finding is in accordance
with the fact that the novel substrate 4-MU-deoxychitobiose
cannot undergo transglycosylation.
Application of Novel Chitotriosidase Assay—The optimal en-
zyme activity assay conditions were determined for the novel
deoxy-substrate. Maximal activity of recombinant chitotriosi-
dase toward the substrate occurs at pH 5.6 with an apparent
Km of about 50 micromolar. An assay mixture composed of 114
M of the deoxy-substrate in 0.1/0.2 M McIlvaine buffer, pH 5.6,
allows the measurement of enzyme activity at maximal rate.
Production of 4-MU is directly proportional to enzyme input
and linear in time over a broad range. The standard assay
mixture described above also allows reliable detection of the
endogenous chitotriosidase in biological samples like plasma,
serum, cerebral spine fluid, urine and extracts of blood cells,
cultured macrophages, and tissues (not shown). This was fur-
ther substantiated by the spiking of increasing amounts of
recombinant chitotriosidase in the various biological samples.
Linearity with time and proportionality to sample input were
also examined.
For reason of maximal sensitivity, subsaturating concentra-
tions of 4-MU-chitobiose or 4-MU-chitotriose had to be used in
enzymatic assays (1). Although the intra-assay reproducibility
with the published method is satisfactory, the inter-assay re-
producibility is intrinsically poor due to unavoidable differ-
ences in precise substrate concentration. Moreover, the propor-
tionality with enzyme input of such assays is relatively limited.
In comparison with enzyme assays with the conventional
4-MU-chitobiose or 4-MU-chitotriose substrate, the enzyme as-
FIG. 3. Demonstration of natural chitooligosaccharide as donor and acceptor for transglycosylation process. Recombinant 50-kDa
chitotriosidase was incubated for different time periods with 5 mM chitopentaose in 50 mM acetate buffer, pH 5.2. Reactions were stopped by placing
samples in boiling water. A, example of HPLC profile (40-min time incubation). B, Overview of concentrations of all chitooligosaccharides. C,
magnification for less abundant chitooligosaccharides.
SCHEME 1
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say with the novel deoxy-substrate is far more sensitive, linear
in time, and directly proportional to enzyme input over a far
larger range (see Fig. 6 for an illustration).
DISCUSSION
Nowadays plasma chitotriosidase activity levels are deter-
mined to assist in the clinical management of Gaucher pa-
tients. Plasma chitotriosidase has evolved as an important tool
in decision making in the clinic. For example, initiation of
costly enzyme replacement therapy for Gaucher patients is
considered in many centers when the plasma chitotriosidase
level exceeds a critical threshold level and changes in activity
level serve as guideline for optimalization of dosing regimens
during enzyme replacement therapy of Gaucher patients (8,
14). Obviously, the application of plasma chitotriosidase meas-
urements for these purposes requires highly reliable and re-
producible data while monitoring patients over a large period of
time. The intrinsic limitation of the current chitotriosidase
activity measurement with non-constant and non-saturating
concentrations of 4-MU-chitobiose or 4-MU-chitotriose as sub-
strates is the difficulty to ensure that the measured reaction
rate is reproducibly proportional to enzyme concentration (1).
In our experience, the only way this can be (nearly) accom-
plished when using the conventional 4-MU-chitooligosaccha-
ride substrates is to vary enzyme input meticulously to obtain
a fixed amount of product formation in a defined assay time
period. This laborious approach implies that a sample has to be
measured in duplicate at various dilutions. In sharp contrast,
the assay with the novel substrate allows measurement at
maximal reaction rate that is continuously proportional to en-
zyme concentration. The novel assay is therefore far more
robust and does not require the tedious precautions associated
with the current assay. A significant additional advantage of the
assay with the novel substrate is the 5-fold increase in sensi-
tivity of detection. This is extremely helpful for diagnostic appli-
cations in relation to a variety of disease conditions with rela-
tively modest (2–10-fold) plasma chitotriosidase elevations like
sarcoidosis, thalassemia, and lysosomal lipid storage disorders.
FIG. 4. Synthesis of 4-MU-(4-deoxy)-chitobiose. Structure formulas of starting compound (octaacetylchitobioside) and intermediates (see
“Materials and Methods” for details).
FIG. 5. Chitotriosidase activity toward 4-MU-chiobiose and its
deoxy variant. Human recombinant chitotriosidase was incubated for
15 min with increasing concentrations of 4-MU substrates, and released
4-MU was detected fluorometrically as described under “Materials and
Methods.” Activity toward 4-MU-chitobiose (f), activity toward 4-MU-
deoxy-chiotbiose (Œ) expressed in arbitrary units (Arbs).
FIG. 6. Linearity of enzyme activity with time and enzyme
input. Human recombinant chitotriosidase was incubated with 4-MU-
chiobiose or 4-MU-deoxychitobiose. Incubation time (upper panel) and
enzyme input (lower panel) were varied (indicated as l of recombinant
chitotriosidase stock solution). Activity was measured by fluorometrical
detection of released 4-MU. Arbs, arbitrary units.
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Our demonstration of a marked transglycosidase capacity of
chitotriosidase is not entirely unexpected based on some very
recent literature reports. During the course of our investigation
it was described that family 18 chitinases from plants and
microbes are to a variable extent able to catalyze transglyco-
sylation reactions. A comparative study revealed that plant
family 18 chitinases have a (4)(3)(2)(1)(1)(2)-type
binding cleft, while the microbial family 18 chitinases show a
(2)(1)(1)(2)(3)(4)-type binding cleft. Transglycosyla-
tion is found in the latter, but not in the former. Soaking of
human chitotriosidase crystals with chitooligosaccharides has
so far not been informative in this respect. Despite carrying out
the experiments at pH 10.6 hydrolysis occurred, rendering
electron density maps where only an ordered N-acetylglu-
cosamine dimer could be observed at subsites 2 and 1 (4).
The production of recombinant human chitotriosidase with one
key active site residue, Glu-140, mutated to Asp or Leu has
been earlier described by us (20). The inactive mutant protein
has retained its ability to bind chitooligosaccharides in the
catalytic cleft. The soaking of crystals of inactive mutant chi-
totriosidase with chitooligosaccharides should render a better
insight in reaction mechanism and structural factors control-
ling enzyme function.
It will be of interest to study in greater detail the prerequi-
sites in the catalytic center of chitotriosidase to act as a trans-
glycosidase. Informative should also be a comparison of chito-
triosidase with a highly related, human gastrointestinal
chitinase (21). The enzyme was very recently identified and
characterized by us and named acidic mammalian chitinase
(AMCase) (21). Despite the high degree of homology with the
macrophage chitotriosidase, AMCase has a number of distinct
features. Interestingly, AMCase uniquely shows a dual pH
optimum for hydrolysis. A second optimum of hydrolytic activ-
ity occurs at very low pH (about pH 2.0). AMCase shows a
different ratio of rates of hydrolysis and transglycosylation of
chitooligosaccharides. Particularly at low pH the enzyme
seems less able to act as transglycosylase. This observation
is consistent with the present assumption that AMCase
predominantly fulfils a role as food-processing hydrolase in the
stomach.
The results of our investigation raise intriguing questions
about the evolutionary origin and physiological significance of
the transglycosidase capacity of chitotriosidase. The human
chitotriosidase gene has clearly evolved from a chitinase gene
in primitive organisms, and many elements have been con-
served among species during evolution (10). It is conceivable,
although highly speculative, that transglycosidase activity of
the primitive chitinase of the ancestral unicellular organisms
allowed biosynthetic formation of increasingly larger chitooli-
gosaccharide polymers near their surface. Prior to the evolu-
tion of the more complex, biosynthetic oligosaccharide trans-
ferases using activated sugars, the enzyme could thus have
played a role in the formation of the first generations of pro-
tective coats.
An interesting aspect of the transglycosidase activity of chi-
totriosidase is the ongoing co-formation of chitotetraose while
chitin is degraded. Chitotetraose is a structure that recently
receives considerable attention. Studies in plants have re-
vealed that chitotetraose may act as signaling molecule that
plays important regulatory roles (see for example Ref. 22 for a
recent review). Moreover there are reports that chitotetraose
may influence embryogenesis in zebra fish (23, 24). In view of
this it might be speculated that also in man a challenge with
some chitin-containing organism could result in local genera-
tion of chitotetraose and subsequently elicit further responses
of local cells and the immune system. In this connection it will
be of interest to examine more closely in animals the effects of
administration of chitotetraose.
At present it is generally believed that man completely lacks
endogenous chitin and also endogenous substrates for chiti-
nases (see for example Ref. 25). Our study, however, raises the
question as to whether endogenous compounds act as (tempo-
rary) acceptors for chitobiose moieties transferred by chitotrio-
sidase from chitin-containing infectious organisms. In this
manner endogenous materials and cells could become deco-
rated with chitobiose motives. Such motives could act as a
marker and play a role in local remodeling events that often
occur in sites of infections. In connection with this it will be of
great importance to investigate in more detail the potential
existence of endogenous acceptors of chitobiose moieties. Such
studies should help to reveal whether the transglycosidase
activity of chitotriosidase is just an evolutionary remnant or
still has a physiological function in man.
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